10.1038/s41591-019-0737-3 - Safety and feasibility of anti-CD19 C...

This document has been corrected

Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma

Published Online: 2020-01-20

Journal: Nature Medicine•Publisher: Springer Science and Business Media LLC

Authors: Adrian Bot•Allen Xue•Brenna Hansen•Danielle Vanasse•David F. Stroncek•James N. Kochenderfer•Jennifer N. Brudno•Jeremy J. Rose•John Rossi•Lekha Mikkilineni•Mark Roschewski•Nathalie Scholler•Norris Lam•Philippe Youkharibache•Rashmika Patel•Raul Cachau•Robert Dean•Ronald E. Gress•Steven A. Rosenberg•Yueh-wei Shen

This document has been corrected

Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma

10.1038/s41591-019-0737-3

Published Online: 2020-01-20

Journal: Nature Medicine

NOW

2020-04-14•Correction

Author Correction: Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma

10.1038/s41591-020-0864-x

* information provided by CrossRef

2020-04-14•Correction

10.1038/s41591-020-0864-x

* information provided by CrossRef

2020-01-20•Published

2020-04-14•Correction

Author Correction: Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma

10.1038/s41591-020-0864-x

* information provided by CrossRef

This document has been corrected

Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma

10.1038/s41591-019-0737-3

Published Online: 2020-01-20

Journal: Nature Medicine•Publisher: Springer Science and Business Media LLC